Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.32 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.32 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ABCC8 | Q09428 | 2/20 | 0.31 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7838930 | 0.74 | CYP3A4 (0.36) | MAPTALDH1A1CYP3A4ABCC8KCNJ11 | |
| SCHEMBL1853410 | 0.74 | — | — | |
| SCHEMBL64072 | 0.73 | CYP3A4 (0.33) | MAPTALDH1A1CYP3A4HPGDALOX15 | |
| SCHEMBL28920099 | 0.73 | ALDH1A1 (0.33) | MAPTALDH1A1CYP3A4TDP1SMN1; SMN2 | |
| SCHEMBL28819045 | 0.71 | CYP3A4 (0.32) | MAPTALDH1A1CYP3A4HPGDALOX15 | |
| SCHEMBL9627673 | 0.71 | — | — | |
| SCHEMBL2161282 | 0.70 | NPSR1 (0.33) | NPSR1 | |
| SCHEMBL3607269 | 0.69 | — | — | |
| SCHEMBL7555586 | 0.69 | — | — | |
| SCHEMBL2302179 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-61109702-A | — | — | None | — | — | JP | disclosed |
| US-20250122171-A1 | Substituted Amine Compounds, Compositions and Methods of Use | DEEP APPLE THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| WO-2025064534-A1 | SUBSTITUTED AMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | DEEP APPLE THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| EP-2406262-B1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LTD (NZ) | 2016-02-17 | — | — | EP | disclosed |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-01-07 | — | — | US | disclosed |
| US-9073916-B2 | Prodrug forms of kinase inhibitors and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-07 | — | — | US | disclosed |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | disclosed |
| JP-S61109702-A | IMIDAZOLE BASED HERBICIDE | SUMITOMO CHEM CO LTD | 1986-05-28 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122171-A1 | Substituted Amine Compounds, Compositions and Methods of Use | MRGPRX2, MRGPRX1, MRGPRX4 | MAPT 3391/4885ALDH1A1 2569/4885CYP3A4 2831/4885 |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | MAPT 3315/4885ALDH1A1 3257/4885CYP3A4 923/4885 |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | MAPT 3259/4885ALDH1A1 3205/4885CYP3A4 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.